Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Tanuja Chitnis, M.D.

Co-Author

This page shows the publications co-authored by Tanuja Chitnis and Bonnie Glanz.
Connection Strength

7.752
  1. Estimating the association between physical activity and health-related quality of life in individuals with multiple sclerosis. Mult Scler Relat Disord. 2022 Sep; 65:104006.
    View in: PubMed
    Score: 0.246
  2. Early Predictors of Clinical and MRI Outcomes Using Least Absolute Shrinkage and Selection Operator (LASSO) in Multiple Sclerosis. Ann Neurol. 2022 07; 92(1):87-96.
    View in: PubMed
    Score: 0.243
  3. Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS. Mult Scler J Exp Transl Clin. 2022 Jan-Mar; 8(1):20552173211069348.
    View in: PubMed
    Score: 0.238
  4. Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. Qual Life Res. 2022 Jun; 31(6):1799-1805.
    View in: PubMed
    Score: 0.235
  5. Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. Mult Scler J Exp Transl Clin. 2021 Apr-Jun; 7(2):20552173211015503.
    View in: PubMed
    Score: 0.228
  6. The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Apr-Jun; 7(2):20552173211007523.
    View in: PubMed
    Score: 0.227
  7. Serum neurofilament levels and patient-reported outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2021 03; 8(3):631-638.
    View in: PubMed
    Score: 0.222
  8. An At-home Positive Psychology Intervention for Individuals with Multiple Sclerosis: A Phase 1 Randomized Controlled Trial. Int J MS Care. 2021 May-Jun; 23(3):128-134.
    View in: PubMed
    Score: 0.216
  9. Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. Mult Scler. 2021 04; 27(4):593-602.
    View in: PubMed
    Score: 0.210
  10. Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. Mult Scler Relat Disord. 2020 May; 40:101944.
    View in: PubMed
    Score: 0.207
  11. Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. NPJ Digit Med. 2019; 2:123.
    View in: PubMed
    Score: 0.206
  12. Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. NPJ Digit Med. 2019 Dec 11; 2(1):123.
    View in: PubMed
    Score: 0.206
  13. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019 Oct; 35:119-127.
    View in: PubMed
    Score: 0.200
  14. Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. Mult Scler J Exp Transl Clin. 2019 Jan-Mar; 5(1):2055217319828400.
    View in: PubMed
    Score: 0.195
  15. Food allergies are associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019 06; 90(6):629-635.
    View in: PubMed
    Score: 0.192
  16. Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis. Mult Scler. 2019 11; 25(13):1791-1799.
    View in: PubMed
    Score: 0.190
  17. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1478-1491.
    View in: PubMed
    Score: 0.190
  18. Short Report: A Pilot Study of a Group Positive Psychology Intervention for Patients with Multiple Sclerosis. Int J MS Care. 2018 May-Jun; 20(3):136-141.
    View in: PubMed
    Score: 0.184
  19. Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients. Mult Scler. 2019 03; 25(3):344-351.
    View in: PubMed
    Score: 0.180
  20. Depression and fatigue in patients with multiple sclerosis. J Neurol Sci. 2017 Sep 15; 380:236-241.
    View in: PubMed
    Score: 0.175
  21. The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. Mult Scler Relat Disord. 2017 Oct; 17:47-53.
    View in: PubMed
    Score: 0.173
  22. Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients. Mult Scler. 2018 07; 24(8):1126-1130.
    View in: PubMed
    Score: 0.173
  23. Oral contraceptives and MS disease activity in a contemporary real-world cohort. Mult Scler. 2018 02; 24(2):227-230.
    View in: PubMed
    Score: 0.169
  24. Risk attitudes and risk perceptions in individuals with multiple sclerosis. Mult Scler J Exp Transl Clin. 2016 Jan-Dec; 2:2055217316665406.
    View in: PubMed
    Score: 0.164
  25. Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e167.
    View in: PubMed
    Score: 0.155
  26. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. 2016 06; 22(7):935-43.
    View in: PubMed
    Score: 0.154
  27. The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS. Neurology. 2015 Oct 06; 85(14):1209-13.
    View in: PubMed
    Score: 0.153
  28. Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis. Mult Scler. 2016 Mar; 22(3):354-61.
    View in: PubMed
    Score: 0.150
  29. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler. 2014 Oct; 20(12):1584-92.
    View in: PubMed
    Score: 0.139
  30. Treatment satisfaction in multiple sclerosis. Int J MS Care. 2014; 16(2):68-75.
    View in: PubMed
    Score: 0.136
  31. No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurol. 2013 Jul 03; 13:73.
    View in: PubMed
    Score: 0.132
  32. Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Mult Scler Int. 2013; 2013:189624.
    View in: PubMed
    Score: 0.129
  33. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. Value Health. 2012 Dec; 15(8):1029-35.
    View in: PubMed
    Score: 0.126
  34. The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. Qual Life Res. 2012 Dec; 21(10):1677-84.
    View in: PubMed
    Score: 0.119
  35. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry. 2012 Jan; 83(1):38-43.
    View in: PubMed
    Score: 0.115
  36. Patient reported outcomes in benign multiple sclerosis. Mult Scler. 2011 Jul; 17(7):876-84.
    View in: PubMed
    Score: 0.112
  37. A method for evaluating treatment switching criteria in multiple sclerosis. Mult Scler. 2010 Dec; 16(12):1483-9.
    View in: PubMed
    Score: 0.108
  38. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler. 2009 May; 15(5):627-31.
    View in: PubMed
    Score: 0.098
  39. Gut Microbiome in Progressive Multiple Sclerosis. Ann Neurol. 2021 06; 89(6):1195-1211.
    View in: PubMed
    Score: 0.057
  40. Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Apr-Jun; 7(2):2055217321999070.
    View in: PubMed
    Score: 0.056
  41. Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. J Psychosom Res. 2020 11; 138:110252.
    View in: PubMed
    Score: 0.054
  42. History of fatigue in multiple sclerosis is associated with grey matter atrophy. Sci Rep. 2019 10 14; 9(1):14781.
    View in: PubMed
    Score: 0.051
  43. Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. Mult Scler. 2020 11; 26(13):1708-1718.
    View in: PubMed
    Score: 0.050
  44. The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. J Neurol Sci. 2019 Aug 15; 403:38-43.
    View in: PubMed
    Score: 0.049
  45. The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurol. 2019 Feb 12; 19(1):23.
    View in: PubMed
    Score: 0.049
  46. Time between expanded disability status scale (EDSS) scores. Mult Scler Relat Disord. 2019 May; 30:98-103.
    View in: PubMed
    Score: 0.048
  47. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. J Neurol Sci. 2018 11 15; 394:127-131.
    View in: PubMed
    Score: 0.047
  48. Identification of MS-specific serum miRNAs in an international multicenter study. Neurol Neuroimmunol Neuroinflamm. 2018 Sep; 5(5):e491.
    View in: PubMed
    Score: 0.047
  49. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. 2018 Aug; 58(2):261-269.
    View in: PubMed
    Score: 0.046
  50. Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis. J Neuroimaging. 2018 05; 28(3):273-277.
    View in: PubMed
    Score: 0.045
  51. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2017 Nov; 18:196-201.
    View in: PubMed
    Score: 0.044
  52. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. J Neuroimaging. 2017 09; 27(5):481-485.
    View in: PubMed
    Score: 0.042
  53. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016 Oct; 3(5):e267.
    View in: PubMed
    Score: 0.041
  54. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients. Mult Scler. 2016 12; 22(14):1841-1849.
    View in: PubMed
    Score: 0.040
  55. Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation. J Neuroinflammation. 2015 Dec 30; 12:245.
    View in: PubMed
    Score: 0.039
  56. Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure. Mult Scler Relat Disord. 2015 Nov; 4(6):598-606.
    View in: PubMed
    Score: 0.038
  57. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. J Neurol. 2015 Nov; 262(11):2425-32.
    View in: PubMed
    Score: 0.038
  58. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport. 2014 Oct 01; 25(14):1156-61.
    View in: PubMed
    Score: 0.036
  59. Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One. 2013; 8(3):e59707.
    View in: PubMed
    Score: 0.032
  60. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.030
  61. A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. PLoS One. 2010 Nov 30; 5(11):e14169.
    View in: PubMed
    Score: 0.028
  62. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17; 75(7):634-40.
    View in: PubMed
    Score: 0.027
  63. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.